Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats.
- Author:
Ying-li LU
1
;
Ying-nan WANG
;
Li ZHANG
;
Lan ZHU
;
Jiang-bo ZHAO
;
Hui WU
;
Ning-cun WANG
;
Xue-fang WANG
;
Dan-lu YU
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cardiomyopathies; drug therapy; etiology; pathology; Cardiotonic Agents; therapeutic use; Diabetes Mellitus, Experimental; complications; drug therapy; Hypoglycemic Agents; therapeutic use; Ligands; Male; Myocardium; ultrastructure; PPAR gamma; therapeutic use; Rats; Rats, Sprague-Dawley; Thiazolidinediones; therapeutic use
- From: Journal of Zhejiang University. Medical sciences 2006;35(3):245-250
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the protective effect of PPARgamma ligands rosiglitazone on myocardium in diabetic cardiomyopathy of rats.
METHODSThe rat model of diabetes was induced by administration of streptozotocin (STZ) for 6 or 10 weeks. In the treatment group the STZ-induced diabetic rats were treated with rosiglitazone. The left ventricular muscle specimens were taken from treatment and control group; then were examined under transmission electron microscope.
RESULTCardiac myofibrils of diabetic rats in control group were obviously fewer and broken. There were fewer and smaller dissolved mitochondria with incomplete membrane and mixed cristae and karyopyknosis. Myocardium of diabetic rats treated with rosiglitazone was markedly improved although their blood glucose levels were still high.
CONCLUSIONHyperglycemia can cause destruction of myocardial cell structure. Rosiglitazone has protective effect on myocardial cells of diabetic rats, which seems to be independent of blood glucose levels.
